薬物依存治療薬のIndiviorが普通株をロンドン証券取引所に公式上場

AsiaNet 59044 （1421）

【スラウ（英国）2014年12月23日PRN=共同通信JBN】Indivior PLC（LON: INDV）（以下Indivior）は、同社の7億1857万7616株の普通株式が英国上場管理機関（UKLA）のプレミアム上場セグメントに公式上場（Official List）を認められたことによって、グリニッジ標準時23日午前8時にロンドン証券取引所メーン市場で取引が始まった。Indiviorはティッカー名「INDV」で取引される。Indiviorは慢性的薬物依存症と関連するメンタルヘルス障害に対するより広範な治療アクセスと先駆的な革新的治療法にコミットしている世界的なスペシャリティーファーマ企業である。

Indiviorのショーン・サクスター最高経営責任者（CEO）は「これはIndivior、株主、われわれが世界でサービスを提供する患者にとってわくわくする瞬間である。われわれはReckitt Benckiser PharmaceuticalsとしてReckitt Benckiserグループとともに長足の進歩を遂げ、今や自社集中的な目的意識と管理の下で、世界的な薬物依存治療に道を開く努力を継続する機会を得た。このほど執行役委員会と取締役会のメンバーを選出、治療の利用拡大と医薬品パイプライン増強によって、Indiviorの将来に確信を抱いている。われわれはペイシェントジャーニー（患者の闘病）に対する理解を積み重ねて、オピオイド依存症の治療を進め、より幅広い薬物まん延とその他メンタルヘルス上の疾患と闘う新しい解決法を市場に持ち込む事業を続けていく」と語った。

Reckitt Benckiserグループ（以下RBグループ）は2014年7月、別個の英国上場によってReckitt Benckiser Pharmaceuticals事業の分割を積極的に進めると発表した。株主は2014年12月11日に開かれたRBグループ総会で、会社分割に賛成票を投じた。RBグループの株主は分割の際に、RBグループが所有する普通株式1株に付きIndiviorの普通株式1株を受け取った。RBグループの普通株式は、引き続きシンボルマーク「RB-LN」で取引される。

▽Indiviorについて

Indiviorは現代の薬物依存治療法に革命をもたらす、患者の擁護、健康政策、証拠に基づく最善の療法モデルで20年のリーダーシップの遺産を持つ世界的なスペシャリティーファーマ企業である。Indiviorの名前は個人を表す「individual」と努力を表す「endeavor」を融合したものであり、キャッチコピーの「Focus on you（あなたに力を注ぐ）」によって会社のコミットメントを鮮明にしている。Indiviorはよく知られ治療中の慢性疾患に対する世界的な人類の危機から薬物依存を転換することに注力している。Indiviorは、薬物中毒治療合剤サビキソン（SUBOXONE、（R）舌下フィルム（CIII）、サビキソン（SUBOXONE、ブプレノルフィンとナルキソン合剤）（R）舌下タブレット、サブテックス（SUBUTEX）（R）舌下タブレットなど、強く世界的なオピオイド依存症用薬品類に基づいて、この範ちゅうにおける伝統をさらに拡大し、オピオイド過剰摂取、アルコール使用疾患、コカイン中毒症などその他慢性薬物依存症を対象とする強固な製品候補パイプラインを保有している。同社はまた、統合失調症など関連するメンタルヘルス障害の新しい医薬候補を探求している。Indiviorは米国のバージニア州リッチモンドに本社を置き、世界で700人以上を雇用、そのポートフォリオは世界の40カ国以上で手に入る。

ソース：Indivior PLC

▽問い合わせ先

メディア

Justine McIlroy | Anna Carruth, Brunswick Group

+44207 404 5959

Beth Keshishian, Biosector 2

+1 212-229-8417

bkeshishian@biosector2.com

投資家

Tom Corran, Indivior, Director, Investor Relations

+44(0)175 321 7800

INDIVIOR PLC Admission to the Official List and to Trading on the London Stock Exchange

PR59044

SLOUGH, United Kingdom, Dec. 23, 2014 /PRN=KYODO JBN/ --

    -- NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION (IN WHOLE OR IN PART) IN,

       INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A

       VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION. THIS ANNOUNCEMENT

       IS NOT A PROSPECTUS BUT AN ADVERTISEMENT AND INVESTORS SHOULD NOT

       ACQUIRE ANY ORDINARY SHARES IN INDIVIOR PLC EXCEPT ON THE BASIS OF THE

       INFORMATION CONTAINED IN THE PROSPECTUS PUBLISHED BY INDIVIOR PLC ON 17

       NOVEMBER 2014 AND ANY SUPPLEMENT OR AMENDMENT THERETO

    Indivior PLC (LON: INDV) ("Indivior") will begin trading on the London

Stock Exchange's main market at 8 a.m. GMT today following the admission of

718,577,616 of its ordinary shares to the premium listing segment of the

Official List of the UK Listing Authority. Indivior will trade under the ticker

"INDV". Indivior is a global specialty pharmaceutical company committed to

expanding treatment access and pioneering innovative therapies for the chronic

diseases of addiction and related mental health disorders.

    "This is an exciting time for Indivior, our shareholders and the patients

we serve worldwide. We made great strides with Reckitt Benckiser Group's

support as Reckitt Benckiser Pharmaceuticals, and we now have the opportunity

to continue our efforts to transform the global addiction treatment landscape

under our own, focused direction and management. With the recent selection of

the Executive Committee and Board of Directors, our experience in expanding

treatment accessibility and our growing pipeline, we are confident in

Indivior's future," said Shaun Thaxter, Chief Executive Officer of Indivior.

"We are building upon our understanding of the patient journey to continue

bringing to market novel solutions that advance treatment in opioid dependence

and combat broader addiction epidemics and other mental health disorders."

    In July 2014, the Reckitt Benckiser Group (the "RB Group") announced it was

pursuing a demerger of the Reckitt Benckiser Pharmaceuticals business with a

separate UK listing. At the RB Group General Meeting on December 11, 2014,

shareholders voted in favour of the demerger.  In the demerger, RB Group

shareholders have received one ordinary share in Indivior for each ordinary

share in RB Group that they hold.  RB Group's ordinary shares will continue

trading under the symbol RB-LN.

About Indivior

    Indivior is a global specialty pharmaceutical company with a 20-year legacy

of leadership in patient advocacy, health policy and evidence-based best

practice models that have revolutionized modern addiction treatment. The name

is the fusion of the words individual and endeavor, and the tagline "Focus on

you" makes the company's commitment clear. Indivior is dedicated to

transforming addiction from a global human crisis to a recognized and treated

chronic disease. Building on its robust, global opioid dependence portfolio

featuring SUBOXONE(R) (buprenorphine and naloxone) Sublingual Film (CIII),

SUBOXONE(R) (buprenorphine and naloxone) Sublingual Tablet and SUBUTEX(R)

(buprenorphine) Sublingual Tablet, Indivior has a strong pipeline of product

candidates designed to both expand on its heritage in this category and address

other chronic diseases of addiction - including opiate overdose, alcohol use

disorders and cocaine intoxication. It also is pursuing novel product

candidates in related mental health disorders such as schizophrenia.

Headquartered in the United States in Richmond, Va., Indivior employs more than

700 individuals globally and its portfolio is available in over 40 countries

worldwide. Visit www.Indivior.com to learn more.

Disclaimers

    This document does not constitute an offer of securities for sale or a

solicitation of an offer to purchase securities in any jurisdiction.

    The ordinary shares of Indivior have not been and will not be registered

under the Securities Act of 1933, as amended (the "Securities Act"), or under

the securities laws of any state or other jurisdiction of the US and may not be

offered or sold within the US, except pursuant to an applicable exemption from,

or in a transaction not subject to, the registration requirements of the

Securities Act and in compliance with any applicable securities laws of any

state or other jurisdiction of the US. There has been no public offering of the

ordinary shares of Indivior in the US for the purposes of the Securities Act.

    This announcement may contain forward-looking statements that are based on

current expectations or beliefs, as well as assumptions about future events.

Although we believe our expectations, beliefs and assumptions are reasonable,

reliance should not be placed on any such statements because, by their very

nature, they are subject to known and unknown risks and uncertainties and can

be affected by other factors that could cause actual results, and our plans and

objectives, to differ materially from those expressed or implied in the

forward-looking statements. You are cautioned not to place undue reliance on

any forward-looking statements, which speak only as of the date hereof. Neither

Indivior nor any other person undertakes any obligation to revise or update any

forward-looking statement contained within this announcement, regardless of

whether those statements are affected as a result of new information, further

events or otherwise. Past performance is not an indicator of future performance.

SOURCE: Indivior PLC

CONTACT:  Media, Justine McIlroy | Anna Carruth, Brunswick Group, +44207 404

5959, Beth Keshishian, Biosector 2, +1 212-229-8417,

bkeshishian@biosector2.com, or Investor, Tom Corran, Indivior, Director,

Investor Relations, +44(0)175 321 7800